Craig Beavers, PharmD Breaks Down the 2026 CKM Guidelines — And Why They Matter

In this solo episode of the Tell-Tale Heart podcast, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, delivers an immediate reaction to the newly released 2026 AHA/ACC/ADA/ASN guidelines for cardiovascular kidney metabolic (CKM) syndrome. Beavers calls the document a landmark framework that formally unites obesity, diabetes, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease into a single disease continuum—a shift he argues changes everything about how clinicians should approach prevention. He walks through the CKM staging system and highlights key updates, including the elevation of albuminuria from an optional to an essential component of cardiovascular risk assessment, the growing role of the PREVENT risk equation, and strong recommendations for SGLT2 inhibitors and finerenone (Kerendia; Bayer) across the CKM spectrum. Beavers also discusses emerging data from the FINE-CKD trial and the 2026 ADA Scientific Sessions, suggesting cardiorenal benefits of finerenone may extend beyond patients with diabetes. He closes by emphasizing that pharmacists are uniquely positioned to lead CKM implementation, serving as connective tissue across specialties in an era of proactive, whole-patient cardiovascular care.